Aesthetic Medical Partnership takes over UKI distribution of Cellenis PRP

Aesthetic Medical Partnership (AMP) will be taking over the distribution of Cellenis Platelet Rich Plasma (PRP) in the UK and Ireland from Medira.

The distribution deal will begin on April 1, 2024, and will see Cellenis PRP join AMP’s existing biologics portfolio, which includes the plant-derived ExtraCellular Nano Complex system, EXO|E for skin and DE|RIVE for scalp and hair.

The company will also spearhead the UK launch of Cellenis PRP DermaFiller – a fully autologous regenerative volumiser – to the UK market in the coming months, further developing its focus on the growing regenerative area of aesthetic medicine.

AMP co-founder and director Martyn Roe said, “We are delighted to be building on the firm foundations Medira have already laid in the UK market and are excited to grow the Cellenis brand. Cellenis PRP is the number one PRP provider in the US, and we look forward to adding Cellenis customers to our growing list of AMP partners.

“To further develop our focus on regenerative medicine, we are particularly excited to launch Cellenis PRP DermaFiller, a fully autologous regenerative volumiser, in the UK market in the next few months.”